Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Current Volume Under High-rate Nasal Oxygen Therapy During Acute Hypoxemic Respiratory Failure de Novo (IVOXY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03919331
Recruitment Status : Unknown
Verified March 2019 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was:  Not yet recruiting
First Posted : April 18, 2019
Last Update Posted : May 16, 2019
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

De novo acute hypoxemic respiratory failure (AHRF) is associated with high overall mortality, which increases significantly with the use of orotracheal intubation. High flow nasal canula (HFNC) has turned to be the first line non-invasive oxygenation strategy aiming to avoid intubation. One of the main factors worsening lung injury and increasing mortality in invasively ventilated patients is a too high tidal volume (TV) delivered by the ventilator. Consistent data suggest that such an aggravation of respiratory lesions may occur during spontaneous ventilation if TV is too large. This phenomenon is called Patient self-inflicted lung injury (P-SILI). The effect of TV on the outcome of patients with de novo AHRF under HFNC has never been evaluated since TV is not easily accessible in patients under HFNC. Investigators hypothesized that a large TV during HFNC has an impact on the outcome. TV will be measured using chest Electrical Impedance Tomography (EIT). To calibrate the EIT data, i.e. to be able to convert changes in thoracic impedance into TV, thoracic impedance signal, flow and volume will be collected during a 4 cmH2O continuous positive airway pressure (CPAP) test, using a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece. Such a level of CPAP is supposed to reproduce the majority of the physiological effects of HFNC. Thus, EIT signal can be used to calculate TV during HFNC since it remains reliable even when the positive expiratory pressure changes.

A secondary objective is to quantify a respiratory distress index. This quantification will be recorded by respiratory inductance plethysmography (RIP), obtained using two elastic bands equipped with a sensor sensitive to their stretching, one positioned at the level of the thorax, the other at the level of the abdomen. The stretching changes of the two bands during the respiratory cycle allow evaluating their possible asynchronism by calculating the phase angle Investigators want to be able to evaluate up to 6 predictors of HFNC failure in this research with an effect size of 0.15, α risk of 0.05, and a power of 0.8. A number of 55 participants is required. Investigators plan to include 60 patients due to potential withdrawal of consent and/or unusable data.


Condition or disease Intervention/treatment Phase
Acute Hypoxemic Respiratory Failure Diagnostic Test: Assessment of tidal volume using Electrical Impedance Tomography (EIT) during high flow nasal canula(HFNC) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Tidal volume (TV) during high flow nasal canula (HFNC) will be measured using chest Electrical Impedance Tomography (EIT). To calibrate EIT data, i.e. to be able to convert changes in thoracic impedance into TV, thoracic impedance signal, flow and volume will be collected during a 4 cmH2O continuous positive airway pressure (CPAP) test, using a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece. Such a level of CPAP is supposed to reproduce the majority of the physiological effects of HFNC. The quantification of respiratory distress index will be recorded by respiratory inductance plethysmography (RIP), obtained using two elastic bands equipped with a sensor sensitive to their stretching, one positioned at the level of the thorax, the other at the level of the abdomen. The stretching changes of the two bands during the respiratory cycle allow evaluating their possible asynchronism by calculating the phase angle.
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Impact of Current Volume Under High-rate Nasal Oxygen Therapy During Acute Hypoxemic Respiratory Failure de Novo
Estimated Study Start Date : June 1, 2019
Estimated Primary Completion Date : June 3, 2021
Estimated Study Completion Date : September 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Experimental
Every adult patient admitted to the medical intensive care unit for de novo acute hypoxemic respiratory failure, and placed under hign flow nasal canula (HFNC). Inclusion and exclusion criterion are listed elsewhere.
Diagnostic Test: Assessment of tidal volume using Electrical Impedance Tomography (EIT) during high flow nasal canula(HFNC)
After information and consent, patients under HFNC for de novo acute hypoxemic respiratory failure will undergo a ten minutes 4cmH2O continuous positive airway pressure(CPAP) test while monitored with 1)chest Electrical Impedance Tomography (EIT) 2) a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece and connected to a differential pressure sensor, and 3) respiratory inductance plethysmography (RIP). Airway flow signal will be acquired using an analog/digital converter and stored for further analysis with acknowledge software. This will allow converting EIT data into tidal volume (TV), and estimating TV under HFNC. RIP signals will allow evaluating asynchronism between chest and abdomen by calculating the phase angle, thus quantifying respiratory distress. Patients monitored with an arterial catheter, arterial blood gas measurements will be done during CPAP and HFNC. These measures will be collected the first day of HFNC, and everyday up to three days




Primary Outcome Measures :
  1. Failure of high flow nasal canula (HFNC) at day 28 [ Time Frame: Day 28 ]
    Failure of HFNC is defined as death or need for invasive mechanical ventilation


Secondary Outcome Measures :
  1. Tidal volume under high flow nasal canula (HFNC) [ Time Frame: Day 0, Day 1 and Day 2 ]
    Tidal volume will be measured using chest Electrical Impedance Tomography (EIT)

  2. Phase angle computed by respiratory inductance plethysmography (RIP) [ Time Frame: Day 0, Day 1 and Day 2 ]
    Phase angle will be measured by respiratory inductance plethysmography

  3. Respiratory rate [ Time Frame: Day 0, Day 1 and Day 2 ]
    respiratory rate will be measured at each evaluation

  4. pH under high flow nasal canula (HFNC) [ Time Frame: Day 0, Day 1 and Day 2 ]
    pH will be measured via Blood gases

  5. PaO2 under high flow nasal canula (HFNC) [ Time Frame: Day 0, Day 1 and Day 2 ]
    PaO2 will be measured via Blood gases

  6. PaCO2 under high flow nasal canula (HFNC) [ Time Frame: Day 0, Day 1 and Day 2 ]
    PaCO2 will be measured via Blood gases

  7. SaO2 under high flow nasal canula (HFNC) [ Time Frame: Day 0, Day 1 and Day 2 ]
    SaO2 will be measured via Blood gases

  8. Regional tidal volume. [ Time Frame: Day 0, Day 1 and Day 2 ]
    computed by Electrical Impedance Tomography

  9. Mortality [ Time Frame: Day 28, Day90 ]
    Mortality at Day 28, Day 90



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years old
  • HFNC initiated as part of the care
  • Respiratory rate > 25 / minute
  • PaO2/FiO2 ratio < 300 mm Hg
  • PaCO2 < 45 mm Hg
  • Affiliated with a social security system
  • Informed consent signed by the patient, trusted person or family member if the patient is unable to consent

Exclusion Criteria:

  • Acute cardiogenic pulmonary edema
  • Underlying chronic respiratory disease
  • Asthma exacerbation
  • Chronic obstructive pulmonary disease Exacerbation
  • Hemodynamic instability, defined as systolic arterial blood pressure < 90 mm Hg or mean arterial blood pressure < 65 mm Hg or the use of vasopressors
  • Glasgow Coma Score <= 12
  • Contraindication to CPAP (maxillofacial surgery, facial trauma)
  • Refusal of the patient to perform the CPAP test
  • Need for emergency intubation according to the clinician in charge of the patient
  • Patient protected by law
  • Pregnancy or breastfeeding woman

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03919331


Contacts
Layout table for location contacts
Contact: Guillaume CARTEAUX, Doctor +331 49 81 43 85 Guillaume.carteaux@aphp.fr

Locations
Layout table for location information
France
Assistance Publique Hôpitaux de Paris - CHU Henri Mondor - Créteil
Créteil, France, 94010
Contact: Guillaume CARTEAUX, Doctor    +331 49 81 43 85    Guillaume.carteaux@aphp.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Layout table for investigator information
Principal Investigator: Guillaume CARTEAUX, Doctor Assistance Publique Hôpitaux de Paris - CHU Henri Mondor - Créteil
Publications:

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT03919331    
Other Study ID Numbers: APHP180138
First Posted: April 18, 2019    Key Record Dates
Last Update Posted: May 16, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Assistance Publique - Hôpitaux de Paris:
High flow nasal canula / P-SILI/ AHRF / EIT
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Insufficiency
Respiration Disorders
Respiratory Tract Diseases